Dr Lal Pathlabs Ltd

Q2 FY26Healthcare Services

Dr Lal Pathlabs Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q2 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹1,894

Market cap₹31.6K Cr

P/E56.3

Updated23 Aug 2026

Read4 min read

The short version

The company targets revenue growth in the range of 11% to 12% for FY26, maintaining this guidance as of now. The company is targeting a revenue growth range of 11%-12% for FY26 and aims to sustain this trajectory.

From Dr Lal Pathlabs Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

The company targets revenue growth in the range of 11% to 12% for FY26, maintaining this guidance as of now.
Sustained 11%-12% revenue growth without price hikes is planned, driven by increased patient volume and revenue per patient.
Growth drivers include testing network expansion, Swasthfit bundling, portfolio test mix improvement, and geographic and channel mix enhancements.
Expansion focus remains on Delhi NCR and Tier-2/3/4 towns for future scalability.
Pilots for radiology services are underway, with potential growth in integrated diagnostics.
New super specialty testing capabilities are being developed to enhance portfolio complexity and differentiation.
The company plans to add 15-20 new labs and 600-800 new collection centers in FY26 to support volume growth.
Pricing remains stable with no immediate plans for hikes; price increases will be considered around February 2026, based on organic growth confidence.

Profitability & Margins

The company is targeting a revenue growth range of 11%-12% for FY26 and aims to sustain this trajectory.
EBITDA margins are expected to be maintained in the range of 27%-28% for the full year, indicating stable operating profitability.
Earnings per share (EPS) showed growth of 16.4% in Q2 FY26 and 20% in H1 FY26 compared to last year; continued growth is implied through operational efficiency and network expansion.
The company plans to maximize utilization of its expanded network and achieve operating leverage through efficiency improvements.
No immediate price hike planned; focus remains on organic growth through patient volume, network expansion, and portfolio innovation.
Investments in new offerings and technology (AI, digital assets) aim to support sustained growth in revenue and profits.
Strategic initiatives like bundling services and geographic expansion into Tier-2/3 cities underpin future scale and profitability growth.

See what Dr Lal Pathlabs Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Planned CAPEX for the current year is estimated around Rs. 130-140 crore, including:
- Maintenance CAPEX of Rs. 50-60 crore.
- Purchase of a new property (Shalimar Bagh) focused on enhancing super specialty testing capabilities.
- Addition of 15 to 20 new labs this financial year.
- Expansion of collection centers by 600 to 800 new points this financial year.
Radiology pilot program:
- Initial outlay for each pilot radiology center (including MRI and CT) between Rs. 12-15 crore.
- Scale-up dependent on pilot outcomes, starting with Delhi NCR.
Ongoing investments in AI and technology for operational efficiency and scaling capabilities.
Focus on inorganic growth in South India via potential M&A, though no specific deals announced yet.

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

5x potential

1Health X Platform₹981 Cr

Rev 1Mar 1

2CHANDAN₹518 Cr

Rev 1Mar 3

3₹66.5K Cr

Rev 2Mar 1

4₹654 Cr

Rev 2Mar 2

5₹1.3L Cr

Rev 2Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
The company highlights strong financials with a net cash balance of Rs. 1,367 crore as of September 30, 2025.
They have announced an interim dividend and a bonus issue of shares, but no discussion on raising additional capital.
The company appears focused on internal growth, network expansion, and operational efficiencies funded through existing resources.
Any future fundraising plans are not indicated or discussed in the call transcript on these pages.

See what Dr Lal Pathlabs Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided transcript from Dr. Lal PathLabs' Q2 & H1 FY26 earnings call does not explicitly mention any details regarding the current or expected order book or pending orders. The discussion primarily focuses on: - Revenue growth and network expansion - Pilot programs in Radiology - Lab utilization and capacity planning - Margin outlook and investment in specialty services like genomics - Market expansion strategies in Tier-2 and Tier-3 cities - Updates on CGHS price revisions and GST benefits No specific information about order backlog or pending orders is shared in the call transcript on page 17 or the surrounding pages.

Dr Lal Pathlabs Ltd — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹703 Cr, net profit ₹132 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Dr Lal Pathlabs's management said in earlier quarters

Others in Healthcare Services this season

Unihealth Hosp (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
Indegene (Q2 FY26)
Indegene is making strategic investments ahead of the curve to capitalize on market opportunities over the next 6 to 8 quarters, which will cause near-term…
Health.Global (Q2 FY26)
Medium-term goal to realize Rs.4,000 crore revenue potential over 4-5 years from current Rs.2,200 crore at existing price points and optimized utilization. Key…
Narayana Hrudaya (Q2 FY26)
CapEx of INR 3000 crores planned over next 3 years in India for expansion, signaling future revenue and earnings growth potential. Key concall takeaways from…

Compare:vs Apollo Hospitals vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Dr Lal Pathlabs Ltd Q2 FY26 results?

What is Dr Lal Pathlabs Ltd share price analysis?

Dr Lal Pathlabs Ltd currently shows a neutral. The stock trades at a P/E of 56.3 with a market cap of ₹31,635 Cr. Investors should review the full earnings analysis for detailed insights.

Is Dr Lal Pathlabs Ltd planning capital expenditure?

Planned CAPEX for the current year is estimated around Rs.

Keep Dr Lal Pathlabs Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.